United Therapeutics (UTHR) Tops Q2 EPS by 22c
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $487.61 --0%
Revenue Growth %: -1.2%
Financial Fact:
Income from continuing operations before income taxes: 239.1M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -1.2%
Financial Fact:
Income from continuing operations before income taxes: 239.1M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $1.34, $0.22 better than the analyst estimate of $1.12. Revenue for the quarter came in at $225.6 million versus the consensus estimate of $213.33 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi turns more bullish on trucking stocks
- GE Aerospace to acquire Consolidated Precision in $11.75b deal
- Freedom Broker Upgrades Costco Wholesale (COST) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
